Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis

Journal of Bone and Mineral Research

Volumn 26, Issue 9, 2011, Pages 1989-1996

  Hansen, Karen E ^a   Wilson, H Alexander ^b   Zapalowski, Carol ^c   Fink, Howard A ^d   Minisola, Salvatore ^e   Adler, Robert A ^d,f  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Bone Health Center   (United States)

^c Denver Center for Bone Health   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DENOSUMAB; ETIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISOLONE; PREDNISONE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; INTERSTITIAL LUNG DISEASE; MEDICAL LITERATURE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; SCLERODERMA; TREATMENT DURATION; VERTEBRA FRACTURE;

DIPHOSPHONATES; FRACTURES, BONE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS; UNCERTAINTY;

EID: 80052007833     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.362     Document Type: Review

References (49)

1. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010; 62: 1515-1526.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333. (Pubitemid 34761611)
3. Frax WHO Fracture Risk Assessment Tool;. 10-14-2008.
4. Shekelle P,. The appropriateness method. Med Decis Making. 2004; 24: 228-231. (Pubitemid 38391941)
5. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001; 44: 1496-1503.
6. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003; 48: 3224-3229. (Pubitemid 37409336)
7. Chappard D, Legrand E, Basle MF, et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res. 1996; 11: 676-685. (Pubitemid 26123919)
8. Dalle Carbonare L, Arlot ME, Chavassieux PM, et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res. 2001; 16: 97-103. (Pubitemid 32046193)
9. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC,. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998; 102: 274-282. (Pubitemid 28335186)
10. Compston J,. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010; 6: 82-88.
11. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998; 339: 292-299. (Pubitemid 28366417)
12. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999; 42: 2309-2318. (Pubitemid 30333410)
13. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373: 1253-1263.
14. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60: 3346-3355.
15. Reid DM, Adami S, Devogelaer JP, Chines AA,. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001; 69: 242-247. (Pubitemid 33035397)
16. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000; 67: 277-285.
17. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44: 202-211. (Pubitemid 32113136)
18. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112: e154-e235.
19. Quintana JM, Escobar A, Arostegui I, et al. Health-related quality of life and appropriateness of knee or hip joint replacement. Arch Intern Med. 2006; 166: 220-226. (Pubitemid 43144947)
20. Hemingway H, Crook AM, Feder G, et al. Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med. 2001; 344: 645-654. (Pubitemid 32183581)
21. Danon-Hersch N, Samartzis D, Wietlisbach V, Porchet F, Vader JP,. Appropriateness criteria for surgery improve clinical outcomes in patients with low back pain and/or sciatica. Spine. 2010; 35: 672-683.
22. Shekelle PG, Kahan JP, Bernstein SJ, et al. The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med. 1998; 338: 1888-1895. (Pubitemid 28287863)
23. Hemingway H, Chen R, Junghans C, et al. Appropriateness criteria for coronary angiography in angina: reliability and validity. Ann Intern Med. 2008; 149: 221-231.
24. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C,. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15: 993-1000. (Pubitemid 30350061)
25. van Staa TP, Leufkens HG, Cooper C,. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13: 777-787. (Pubitemid 36336722)
26. van Staa TP, Geusens P, Pols HA, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM. 2005; 98: 191-198. (Pubitemid 40361316)
27. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25: 2267-2294.
28. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22: 1479-1491. (Pubitemid 351229318)
29. Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [(1-34)rhPTH] in postmenopausal osteoporosis. J Bone Miner Res. 2011; 26: 503-511.
30. Franchimont N, Canalis E,. Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmun Rev. 2003; 2: 224-228. (Pubitemid 36793947)
31. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997; 337: 382-387. (Pubitemid 27328368)
32. Fink HA, Milavetz DL, Palermo L, et al. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res. 2005; 20: 1216-1222. (Pubitemid 40863810)
33. Vokes TJ, Dixon LB, Favus MJ,. Clinical utility of dual-energy vertebral assessment (DVA). Osteoporos Int. 2003; 14: 871-878. (Pubitemid 38009525)
34. Lin JH,. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996; 18: 75-85. (Pubitemid 26092586)
35. Graepel P, Bentley P, Fritz H, Miyamoto M, Slater SR,. Reproduction toxicity studies with pamidronate. Arzneimittelforschung. 1992; 42: 654-667.
36. McKenzie AF, Budd RS, Yang C, Shapiro B, Hicks RJ,. Technetium-99m- methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. J Nucl Med. 1994; 35: 1338-1341. (Pubitemid 24243148)
37. Losada I, Sartori L, Di Gianantonio E, et al. Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of childbearing age? Autoimmun Rev. 2010; 9: 547-552.
38. Hassen-Zrour S, Korbaa W, Bejia I, Saidani Z, Bergaoui N,. Maternal and fetal outcome after long-term bisphosphonate exposure before conception. Osteoporos Int. 2010; 21: 709-710.
39. Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009; 20: 2095-2104.
40. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357: 2028-2039. (Pubitemid 350106710)
41. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000; 15: 1006-1013. (Pubitemid 30350063)
42. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010; 69: 872-875.
43. Adler RA, Curtis J, Weinstein RS, Saag KG,. glucocorticoid-induced osteoporosis. In:, Marcus R, Feldman D, Nelson DA, Rosen CJ, eds. Osteoporosis 3rd ed. Burlington, MA: Elsevier, 1135-1166. 2008.
44. Weinstein RS, Jia D, Powers CC, et al. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology. 2004; 145: 1980-1987. (Pubitemid 38402407)
45. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E,. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab. 1998; 83: 801-806. (Pubitemid 28496450)
46. Montecucco C, Caporali R, Caprotti P, Caprotti M, Notario A,. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol. 1992; 19: 1895-1900. (Pubitemid 23018520)
47. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998; 102: 1627-1633. (Pubitemid 28492231)
48. Reid IR, Wattie DJ, Evans MC, Stapleton JP,. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med. 1996; 156: 1173-1177. (Pubitemid 26196245)
49. Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ,. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab. 2003; 88: 3167-3176. (Pubitemid 36877490)